Navigation Links
Interleukin Genetics Retains Top Life Science Communications Firms

Stern Investor Relations and LaVoie Group Selected as IR, PR Agencies of


WALTHAM, Mass., March 18 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc., (Amex: ILI), announced today that it has retained two premier life science communications firms, Stern Investor Relations, Inc., and LaVoie Group, as agencies of record to provide investor relations and public relations services, respectively.

The two firms will provide strategic counsel and execution, will lead efforts to communicate Interleukin Genetics' vision to use the science of applied genetics to personalize health management and will support the Company's strategy to establish additional partnerships and relationships with biotechnology and pharmaceutical companies.

Lewis H. Bender, Chief Executive Officer commented, "Interleukin Genetics has a strong message on the value of diagnostic testing to empower consumers to personalize their health. With the addition of these two firms, I am confident that we will deliver our message more effectively to our key constituencies."

About LaVoie Group

LaVoie Group provides strategic, integrated marketing and communications- including marketing strategy, corporate communications, as well as public and investor relations to life sciences and healthcare companies. LaVoie Group's clients range from start-ups to industry leaders. For more information, visit

About Stern Investor Relations

Stern Investor Relations provides investor relations consulting services to biotechnology and healthcare companies. Stern IR develops and implements strategic investor relations programs designed to effectively manage communications with the investment community. Founded in 1998, Stern IR offers a full range of investor relations services. For more information, please visit

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward- looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
2. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
5. Interleukin Genetics Announces Management and Board Appointments
6. deCODE genetics to Webcast Presentation at Lehman Brothers Eleventh Annual Global Healthcare Conference
7. deCODE Genetics Announces Full-year 2007 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
9. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
10. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
11. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier ... models, has promoted Melanie Aregger to serve as Chief Operating Officer. , ... the management team and was promoted to Head of InSphero Diagnostics in ...
(Date:11/24/2015)... 2015 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) ... Pierre Laurin , President and Chief Executive Officer of ... Piper Jaffray 27 th Annual Healthcare Conference to be ... 2015. st , at 8.50am (ET) and ... the day. The presentation will be available live via a ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... YORK , November 24, 2015 ... in a European healthcare ... which the companies will work closely together in identifying European ... unmet medical need. The collaboration is underpinned by a significant ... fund. This is the first investment by Bristol-Myers Squibb in ...
Breaking Biology Technology:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):